General Information
Biomea COVALENT-111 Expansion Cohort Metro
A Phase 1/2 Randomized, Double‐Blind, Placebo‐Controlled Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMF‐219, an Oral Covalent Menin Inhibitor, in Healthy Adult Subjects and in Adult Subjects with Type 2 Diabetes Mellitus
| Protocol | Bi01892-1002059-BioF101 |
|---|---|
| Identifier | |
| UID | 89a79013-f9e8-46b7-9bef-5f7160b25fea |
| Status | Done - Archived |
| Phase | 2 |
| Category | Diabetes Type 2/NAFLD / Adult |
| Launch Year | 2022 |
| NCT Number | - |
| Created | 2023-10-10 16:23 |
| Last Updated | 2025-03-17 22:23 |
Description
No description provided.
Comment
No comment.
Target Dates
| Name | Date | Required |
|---|---|---|
| Enrollment Closed | No | |
| Enrollment Open | No | |
| First Patient First Visit | No | |
| Site Initiation Mtg. | 2023-10-25 | No |
| PI Meeting Start | No | |
| PI Meeting End | No | |
| PI Meeting Arrival | No | |
| PI Meeting Departure | No | |
| Closeout Date | 2025-02-27 | No |
| Final PatientVisit | No | |
| PreStudy Selection Visit | No | |
| Target Date 12 | No | |
| Target Date 13 | No | |
| Target Date 14 | No |
Leadership
| Role | Staff | Login | Required |
|---|---|---|---|
| Principal | Casaclang, Cecilia | CCasaclang | No |
| Recruiter | Gomez, Kathie | KGomez | No |
| Coordinator | Meza, Christopher | CMeza | No |
| Regulatory | Romero, Araselly | ARomero | No |
Custom Fields
No custom fields.
Sponsor & Organization
| Sponsor | Biomea Fusion |
|---|---|
| Division | Biomea Fusion |
| Team | Biomea Fusion |
| Managing Site | Metro Clinical Trials - San Bernardino |
| Organization |
Contacts
| IRB Ref | |
|---|---|
| CRO | ProSciento, Inc. |
| CRO Ref | |
| Correspondence | 0 |
Opportunity
| Probability | 0 |
|---|---|
| Comment | |
| Status Color | Gainsboro |
| Currency | - |
